Clinical Trial: Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07783412) titled 'Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum' on July 29.

Brief Summary: This is a single-center, open-label, single-arm pilot study evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers. Approximately 12 participants will apply ruxolitinib cream twice daily for 24 weeks while continuing standard wound care, with the goal of determining whether the drug helps target ulcers heal completely without the need for systemic immunosuppressive therapy. Participants will be followed for a total of 28 week...